SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

Diabetes is the most frequent cause of chronic kidney disease (CKD), leading to nearly half of all cases of kidney failure requiring replacement therapy. The principal cause of death among patients with diabetes and CKD is cardiovascular disease (CVD). Sodium/glucose cotransporter 2 (SGLT2) inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Tuttle, Katherine R., Brosius, Frank C., Cavender, Matthew A., Fioretto, Paola, Fowler, Kevin J., Heerspink, Hiddo J.L., Manley, Tom, McGuire, Darren K., Molitch, Mark E., Mottl, Amy K., Perreault, Leigh, Rosas, Sylvia E., Rossing, Peter, Sola, Laura, Vallon, Volker, Wanner, Christoph, Perkovic, Vlado
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2021
Materias:
Perspectives in Diabetes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162454/
https://www.ncbi.nlm.nih.gov/pubmed/33106255
http://dx.doi.org/10.2337/dbi20-0040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162454/
https://www.ncbi.nlm.nih.gov/pubmed/33106255
http://dx.doi.org/10.2337/dbi20-0040

Ejemplares similares